Brickell Biotech
Miami
About Brickell Biotech
Brickell Biotech, is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $48.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2021)
- Ticker: nasdaq:BBI
- Website: brickellbio.com
- Phone: +1 786-304-2083
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/brickell-biotech-228266 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.